1: (ROOT (S (NP (DT No) (NN evidence) (SBAR (S (NP (NN hydroxychloroquine)) (VP (VBZ treats) (NP (NN coronavirus)))))) (, ,) (NP (QP (NP (JJ new) (NN study)) (QP (RB showsAbout) (CD 1,000))) (NNS patients)) (VP (VBD received) (NP (NP (DT the) (NN chloroquine) (NNS drugs)) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN with) (NP (NP (DT the) (NNS antibiotics)) (NP (NN azithromycin) (CC or) (NN clarithromycin)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (VBG remaining) (CD 8,000)) (VP (VBD did) (RB not))))) (. .)))
2: (ROOT (S (NP (DT The) (NNS findings)) (VP (VBP echo) (NP (NP (JJR smaller) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (NNP New) (NNP York)) (CC and) (NP (NNP Europe)))))))) (. .)))
3: (ROOT (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD took) (NP (DT the) (NNS drugs)))))) (VP (VBD were) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB die) (PP (IN in) (NP (DT the) (NN hospital))))))))) (, ,) (NP (DT the) (NNS researchers)) (VP (VBD found)) (. .)))
4: (ROOT (S (SBAR (IN While) (S (NP (DT that)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (IN in) (NP (NN part))) (PP (IN to) (NP (DT the) (NN likelihood) (SBAR (IN that) (S (NP (DT those) (NNS medicines)) (VP (VBD were) (VP (VBN given) (PP (IN to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJR sicker)))))))))))))))))) (, ,) (NP (NP (DT the) (NNS authors)) (PP (IN of) (NP (DT the) (NN study)))) (VP (VBD estimated) (SBAR (IN that) (S (NP (DT the) (JJ excess) (NN risk)) (VP (VBD ranged) (PP (PP (IN from) (NP (CD 34))) (PP (IN to) (NP (CD 45) (NN percent)))))))) (. .)))
5: (ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN study) (POS 's)) (NNS authors)) (VP (VBD pushed) (PP (IN for) (NP (JJ urgent) (VBN randomized) (, ,) (JJ controlled) (NNS trials))) (, ,) (S (VP (VBG saying) (SBAR (S (NP (NP (PRP it))) (VP (VBZ 's) (RB not) (ADJP (JJ possible)) (PP (IN in) (NP (DT an) (JJ observational) (NN study))) (S (VP (TO to) (VP (VB exclude) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (JJ other) (NNS factors)) (VP (VBD were) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ apparent) (NN link)) (PP (IN between) (NP (NP (NN survival) (NN rate)) (CC and) (NP (DT these) (NNS drugs)))))))))))))))))))) (. .)))
6: (ROOT (S (S (NP (NP (NNS People)) (VP (VBG taking) (NP (NN hydroxychloroquine)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT an) (NN antibiotic))))))) (VP (VBD appeared) (S (VP (TO to) (VP (VB have) (NP (NP (DT the) (JJS highest) (VBN increased) (NN risk)) (PP (IN of) (NP (NML (NN heart) (NN rhythm)) (NNS complications))))))))) (, ,) (NP (DT the) (NN study)) (VP (VBD found)) (. .)))
7: (ROOT (S (S (S (NP (NN Chloroquine)) (VP (VBZ is) (VP (VBN approved) (PP (IN for) (NP (NN malaria)))))) (, ,) (CC and) (S (NP (NN hydroxychloroquine)) (PP (IN for) (NP (NP (JJ autoimmune) (NNS diseases)) (PP (IN like) (NP (NNP Lupus))))))) (: ;) (S (NP (DT the) (NNS authors)) (VP (VBD said) (SBAR (S (NP (DT the) (NN study)) (VP (VBZ does) (RB not) (VP (VB suggest) (SBAR (S (NP (DT those) (NNS patients)) (VP (MD should) (VP (VB stop) (S (VP (VBG taking) (NP (DT the) (NNS drugs)) (SBAR (IN as) (S (VP (VBN prescribed)))))))))))))))) (. .)))
8: (ROOT (S (NP (DT The) (NNP FDA)) (VP (VP (VBD issued) (NP (NP (DT an) (NN emergency) (NN authorization)) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NN coronavirus) (NNS patients)))))) (PP (IN in) (NP (JJ late) (NNP March)))) (, ,) (CC but) (VP (VBZ has) (ADVP (IN since)) (VP (VBN received) (NP (NN criticism)) (PP (IN for) (S (VP (VBG doing) (ADVP (RB so))))) (PP (VBN given) (NP (DT the) (JJ scant) (NN evidence) (SBAR (S (NP (DT the) (NNS drugs)) (VP (VBD worked))))))))) (. .)))
9: (ROOT (S (NP (NNP Sarah) (NNP Wheaton)) (VP (VBD contributed) (PP (IN to) (NP (DT this) (NN report)))) (. .)))
